EnVivo's Pipeline 2/08

		Home \| Company \| Our Team \| Programs \| Publications \| News & Events

EnVivo News & Events

	WATERTOWN, Mass., January 19, 2010 – EnVivo Pharmaceuticals, Inc. has been awarded a research grant by the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will fund research as part of the foundation’s Therapeutics Development Initiative that seeks new treatments for Parkinson’s disease.



	WATERTOWN, Mass., January 5, 2010 – EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.